Donald Trump has said in the past his workers get health coverage from their jobs, and this means they wouldn't have to buy Obamacare plans. » Read More
By: Bertha Coombs
Unlike an flexible savings account, health savings account funds don't expire at the end of the year and they're portable. » Read More
Sen. Bernie Sanders and Rep. Elijah Cummings request details after Ariad repeatedly raised the price of its drug.
A new drug being tested slows Alzheimer's by removing plaque buildup in the brain. It's hope for millions suffering from the disease.
New CEO David Sacks is hoping that a new all-in-one human resources platform for small business will turn the page for Zenefits in 2017.
Eli Lilly is expanding its international operations to target diabetes and tuberculosis in areas lacking access to treatment.
Jefferies shares its favorite biotech stock ideas to pick up amid the recent share price weakness due to Hillary Clinton's rising poll numbers.
A cybersecurity expert explains to CNBC why a breach of a medical device maker could be a new front in the hacking wars.
Martin Shkreli's lawyers previously suggested that his defense would be based on the claim that he had been relying on the advice of his lawyer.
"Pharma bro" Martin Shkreli wanted to visit a Brooklyn bar immediately after his hearing in Brooklyn Friday afternoon, but one establishment put a stop to that.
Medicare ratings cuts at Humana may signal a higher bar for other Medicare insurers, an analyst says.
Humana fell Wednesday after a report by the Centers for Medicare and Medicaid Services showed its membership highly rated Medicare plans declined.
Federal health officials and the drug company Mylan are refusing to explain why full rebates for EpiPen are being delayed.
Illumina shares sink after the company trimmed its third-quarter revenue projections.
Zocdoc wants to make "Unsick Days" common, so workers can get checkups during a paid day off without having to worry about repercussions.
Shares of Bristol-Myers Squibb fell 10 percent, after the Opdivo trial result did not meet expectations.
Mylan soared Monday after it agreed to pay $465 million to settle charges that it overcharged the government for its EpiPen products.
After being largely ignored during the first presidential debate, the Affordable Care Act just got a lot of attention from Clinton and Trump.
Get the best of CNBC in your inbox